719 related articles for article (PubMed ID: 16293972)
1. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
3. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
4. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
[TBL] [Abstract][Full Text] [Related]
5. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
7. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
Delgado Bolton RC; Ortega Candil A; Pérez Castejón MJ; Garcerant M; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
Rev Esp Med Nucl; 2008; 27(2):112-7. PubMed ID: 18367049
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
9. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
[TBL] [Abstract][Full Text] [Related]
10. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Zincirkeser S; Sevinc A; Kalender ME; Camci C
World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
[TBL] [Abstract][Full Text] [Related]
11. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
[TBL] [Abstract][Full Text] [Related]
12. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
[TBL] [Abstract][Full Text] [Related]
13. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
Abhyankar SA; Nair N
Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
[No Abstract] [Full Text] [Related]
14. Esophageal gastrointestinal stromal tumor: report of 7 patients.
Shinagare AB; Zukotynski KA; Krajewski KM; Jagannathan JP; Butrynski J; Hornick JL; Ramaiya NH
Cancer Imaging; 2012 Apr; 12(1):100-8. PubMed ID: 22542728
[TBL] [Abstract][Full Text] [Related]
15. FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Malle P; Sorschag M; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):423-9. PubMed ID: 22890522
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Jager PL; Gietema JA; van der Graaf WT
Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
[TBL] [Abstract][Full Text] [Related]
17. The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Van den Abbeele AD
Oncologist; 2008; 13 Suppl 2():8-13. PubMed ID: 18434632
[TBL] [Abstract][Full Text] [Related]
18. Response evaluation of gastrointestinal stromal tumors.
Choi H
Oncologist; 2008; 13 Suppl 2():4-7. PubMed ID: 18434631
[TBL] [Abstract][Full Text] [Related]
19. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
Otomi Y; Otsuka H; Morita N; Terazawa K; Furutani K; Harada M; Nishitani H
J Med Invest; 2010 Aug; 57(3-4):270-4. PubMed ID: 20847527
[TBL] [Abstract][Full Text] [Related]
20. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
